Maravai Non Currrent Assets Other vs Common Stock Total Equity Analysis
MRVI Stock | USD 5.66 0.11 1.91% |
Maravai Lifesciences financial indicator trend analysis is infinitely more than just investigating Maravai Lifesciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Maravai Lifesciences is a good investment. Please check the relationship between Maravai Lifesciences Non Currrent Assets Other and its Common Stock Total Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Non Currrent Assets Other vs Common Stock Total Equity
Non Currrent Assets Other vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Maravai Lifesciences Non Currrent Assets Other account and Common Stock Total Equity. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Maravai Lifesciences' Non Currrent Assets Other and Common Stock Total Equity is -0.68. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Maravai Lifesciences Holdings, assuming nothing else is changed. The correlation between historical values of Maravai Lifesciences' Non Currrent Assets Other and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Maravai Lifesciences Holdings are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Non Currrent Assets Other i.e., Maravai Lifesciences' Non Currrent Assets Other and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | -0.68 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Maravai Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Maravai Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. The Maravai Lifesciences' current Enterprise Value is estimated to increase to about 3.1 B, while Tax Provision is forecasted to increase to (1.5 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 30.3M | 20.4M | 45.9M | 33.9M | Depreciation And Amortization | 24.8M | 38.1M | 48.8M | 33.8M |
Maravai Lifesciences fundamental ratios Correlations
Click cells to compare fundamentals
Maravai Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Maravai Lifesciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 577.8M | 1.3B | 1.9B | 2.3B | 1.5B | 1.5B | |
Short Long Term Debt Total | 390.2M | 590.8M | 534.3M | 585.3M | 611.0M | 559.4M | |
Other Current Liab | 18.7M | 40.8M | 64.3M | 88.3M | 59.5M | 55.1M | |
Total Current Liabilities | 29.6M | 130.8M | 93.8M | 110.1M | 87.5M | 89.4M | |
Total Stockholder Equity | 141.4M | 88.5M | 315.5M | 545.2M | 416.8M | 302.8M | |
Other Liab | 15.9M | 400.4M | 713.6M | 693.4M | 797.4M | 405.2M | |
Net Tangible Assets | (280.7M) | (313.4M) | 315.5M | 44.9M | 51.6M | 54.2M | |
Property Plant And Equipment Net | 94.3M | 101.3M | 46.3M | 116.6M | 222.6M | 114.4M | |
Current Deferred Revenue | 841K | 78.1M | 10.2M | 3.1M | 3.4M | 3.2M | |
Net Debt | 365.5M | 354.6M | (17.0M) | (46.9M) | 36.0M | 34.2M | |
Retained Earnings | (42.4M) | 854K | 184.6M | 404.8M | 285.7M | 145.8M | |
Accounts Payable | 7.5M | 3.0M | 8.2M | 6.0M | 10.7M | 7.1M | |
Cash | 24.7M | 236.2M | 551.3M | 632.1M | 575.0M | 374.2M | |
Non Current Assets Total | 517.2M | 939.1M | 1.2B | 1.4B | 787.5M | 979.4M | |
Non Currrent Assets Other | 805K | 4.2M | 52.9M | 40.3M | 9.3M | 8.9M | |
Other Assets | 805K | 435.9M | 812.5M | 806.1M | 927.0M | 973.4M | |
Long Term Debt | 334.8M | 528.6M | 524.6M | 522.0M | 518.7M | 506.8M | |
Cash And Short Term Investments | 24.7M | 236.2M | 551.3M | 632.1M | 575.0M | 374.2M | |
Net Receivables | 18.0M | 51.0M | 117.5M | 146.8M | 55.7M | 74.3M | |
Liabilities And Stockholders Equity | 577.8M | 1.3B | 1.9B | 2.3B | 1.5B | 1.5B | |
Non Current Liabilities Total | 403.6M | 985.2M | 1.3B | 1.3B | 610.1M | 898.5M | |
Capital Lease Obligations | 52.9M | 56.2M | 3.7M | 57.8M | 86.8M | 47.5M | |
Inventory | 14.2M | 33.3M | 51.6M | 43.2M | 51.4M | 38.1M | |
Other Current Assets | 3.6M | 11.1M | 19.7M | 25.8M | 17.8M | 14.6M | |
Other Stockholder Equity | 8.0M | 85.1M | 128.4M | 137.9M | 128.5M | 90.2M | |
Total Liab | 433.2M | 1.1B | 1.4B | 1.4B | 697.6M | 987.9M | |
Net Invested Capital | 478.7M | 623.1M | 846.1M | 1.1B | 940.9M | 814.7M | |
Property Plant And Equipment Gross | 94.3M | 101.3M | 46.3M | 136.1M | 254.9M | 267.6M | |
Total Current Assets | 60.6M | 331.6M | 740.0M | 847.9M | 699.9M | 501.2M | |
Capital Stock | 183.9M | 2.6M | 2.6M | 2.6M | 2.5M | 2.4M | |
Non Current Liabilities Other | 1.2M | 2.2M | 754.5M | 17.4M | 2.4M | 2.3M | |
Net Working Capital | 31.0M | 200.8M | 646.3M | 737.8M | 612.4M | 411.8M | |
Intangible Assets | 197.9M | 177.7M | 117.6M | 216.7M | 221.0M | 210.6M | |
Common Stock | 183.9M | 2.6M | 2.6M | 2.6M | 2.5M | 2.4M | |
Property Plant Equipment | 94.3M | 101.3M | 46.3M | 116.6M | 134.1M | 88.2M |
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.